PALO ALTO, Calif.--(BUSINESS WIRE)--Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that Medicines for Malaria Venture (MMV) has extended the existing development agreement between the two organizations to fund the clinical development of AN3661, a boron-based drug candidate for the treatment of malaria. On April 26, 2010, Anacor and MMV entered into a research collaboration to apply Anacor’s boron chemistry to identify new medicines to treat malaria. On March 17, 2011, the two organizations entered into a development agreement for AN3661, the first candidate arising from the research collaboration to enter into preclinical development. At that time, MMV agreed to provide funding for the preclinical studies. Under the expanded agreement, MMV will provide additional funding to allow completion of the Phase 1 clinical trials and a human proof-of-concept study in malaria.
